Antiplatelet treatment in patients with diabetes mellitus: is there a difference between aspirin, clopidogrel and prasugrel - Antiplatelet Treatment in Diabetes

niversity of Leeds0 个研究点目标入组 56 人开始时间: 2010年3月15日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•Age 18 - <75
•Type 2 diabetes mellitus
•currently taking aspirin 75mg per day
•Weight 60kg or over
•Must be able to give informed consent and comply with the protocol
•Using reliable contraception ie. oral contraceptive pill, intra-uterine device, diaphragm + condom
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•prior treatment with clopidogrel or prasugrel
•previous or current treatment with warfarin or non-steroidal inflammatory drugs
•a history of acute coronary syndrome within 3 months of recruitment
•any history of coagulation or bleeding disorder, neoplastic disease, deep vein thrombosis, pulmonary embolism. Any previous or current upper gastrointestinal pathology
•any history of cerabral vascular accident or transient ischaemic attack
•hypersensitiviy to the active substance (ie clopidogrel or prasugrel) or any of the excipients
•active pathological bleeding
•any individual found to have abnormal liver function (measured by ALT>3times upper limit of normal) or abnormal thyroid function will be excluded at this time and offered further investigation
•Weight less than 60kg
•inadequate contraception (as described in inclusion criteria)
•pregnant and lactating women will be excluded. In the unlikely event of pregnancy during the study, the individual will be immediately withdrawn

发起方

niversity of Leeds